Summary: This fall, The FDA recommended that Teva Neuroscience's drug rasagiline, brand name Azilect, should not be granted status "to slow the clinical progression of PD."
Summary: This fall, The FDA recommended that Teva Neuroscience's drug rasagiline, brand name Azilect, should not be granted status "to slow the clinical progression of PD."